Figure 5
From: Synthetic integrin-binding immune stimulators target cancer cells and prevent tumor formation
In vitro and in vivo analysis of Y9. (A) Chemotaxis of human and murine leukocytes upon stimulation with different concentrations of Y9. (B) Oxidative burst of human, mouse and guinea pig leukocytes upon stimulation with Y9. (C) Immune cell infiltration in nude mice and guinea pig skin (HE stained sections, scale bars 100 µm) 24 h after s.c. injection of 100 nmol (guinea pig) or 500 nmol Y9 (Balb/cnu/nu mice), respectively. (D) SPR measurement of Y9 binding to immobilized integrin α3β1 (VLA-3). (E) Concentration-dependent binding of biotinylated Y9 to A431 cells in the presence or absence of MnCl2 (detected by incubation with PerCP-Cy5.5 labeled streptavidin).
